Indivior Plc Strengthens OUD Commitment Through Investor Engagements and Conferences

Indivior Plc Enhances Commitment to Opioid Use Disorder Management Through Key Investor Engagements

Indivior Plc, a leading global pharmaceutical company headquartered in Richmond, VA, reinforces its commitment to combating the opioid use disorder (OUD) crisis by participating in prominent investor events. On September 8, 2025, Chief Executive Officer Joe Ciaffoni and Chief Financial Officer Ryan Preblick are set to attend the Morgan Stanley 23rd Annual Global Healthcare Conference in New York City. During this conference, they will host both one-on-one meetings and group discussions, facilitating deeper engagement with potential and existing investors about Indivior's strategic vision and operational initiatives. Notably, Ciaffoni will also partake in a fireside chat scheduled for 9:15 a.m. U.S. ET, which will be accessible via a public webcast. This engagement underscores Indivior's dedication to transparency and its ongoing commitment to addressing the OUD crisis.

Following the Morgan Stanley event, Indivior's leadership will participate in the H.C. Wainwright 27th Annual Global Investment Conference on September 9, 2025. This opportunity allows the company to further connect with investors and stakeholders, offering insight into its robust product pipeline and innovative approaches to managing OUD. Indivior's focus on creating evidence-based treatments positions it uniquely within the pharmaceutical sector, aiming to transform OUD into a chronic disease that can be effectively managed. This mission not only highlights the company's dedication to improving patient outcomes but also reflects a broader trend in healthcare where chronic conditions are increasingly recognized and treated with the same rigor as other long-term health issues.

Indivior's efforts extend beyond investor engagement; the company boasts a comprehensive portfolio of OUD medications and is continually expanding its pipeline to enhance treatment options. With over 1,000 employees and products available in more than 30 countries, Indivior is well-positioned to lead in the fight against the opioid crisis. By actively participating in these key conferences, Indivior demonstrates its commitment to engaging with stakeholders while seeking innovative solutions to a pressing public health issue, thereby reinforcing its reputation as a leader in the pharmaceutical industry.

In addition to these events, interested parties can learn more about Indivior's initiatives and product offerings by visiting the company's website or connecting on LinkedIn. As the OUD crisis continues to evolve, Indivior remains committed to its mission of providing effective treatments and fostering a greater understanding of addiction as a manageable chronic disease.